logo-loader
viewRedx Pharma PLC

Redx Pharma unveils second fibrosis drug candidate will enter clinic in the first half of next year

RXC007 has been designed to target ROCK2, a nodal enzyme in cell signalling pathways associated with conditions such as idiopathic pulmonary fibrosis (IPF), a chronic lung condition with a poor prognosis

Redx Pharma Plc -

Redx Pharma PLC (LON:REDX) said its second fibrosis drug candidate will enter the clinic in the first half of next year.

RXC007 has been designed to target ROCK2, a nodal enzyme in cell signalling pathways associated with idiopathic pulmonary fibrosis (IPF), a chronic lung condition with a poor prognosis.

It may also serve as a treatment for a liver disease called non-alcoholic steatohepatitis and a severe kidney problem called diabetic nephropathy.

Early indications from the company’s ROCK2 programme suggest the drug has “robust anti-fibrotic effects” and that it can be taken orally. Additionally, it is expected to have a safe cardiovascular profile.

This is the second cab off the rank in the field of fibrosis for Redx. It is also developing RXC006, which is intended to be the first drug in this class for IPF.

"Redx is pleased to be progressing the development of this exciting drug candidate that selectively inhibits ROCK2 as a potential treatment for multiple fibrotic diseases,” said chief executive Lisa Anson.

“This is a challenging area of chemistry and the Redx team is proud to deliver another successful drug candidate.”

Quick facts: Redx Pharma PLC

Price: 14.25 GBX

AIM:REDX
Market: AIM
Market Cap: £27.08 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 rallies as Italians ban short selling

Headlines from the Proactive UK newsroom. The FTSE 100 rallied this morning even though Asian markets suffered more pain overnight.  London’s blue chip index opened around 157 points higher at 5,395 after giving up 639 points yesterday. Italy has introduced a temporary ban on...

2 weeks, 3 days ago

2 min read